How much funding has Genelux raised?

Genelux has disclosed $23.8M raised across 2 of its 10 known rounds.

Where is Genelux headquartered?

Genelux is headquartered in Westlake Village, US.

Genelux

NASDAQ: GNLX

Westlake Village, US · Delaware corporation

Find your way into Genelux

Paths you didn't know you had: your email and LinkedIn already hold routes to the Genelux team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Genelux Corporation develops next-generation immunotherapies for patients with aggressive and difficult-to-treat solid tumors, running clinical trials and offering physician-requested expanded access to its investigational drugs under limited conditions. The company operates in the biotech and oncology therapeutics space.

Biotech Medical Devices

Founders & leadership

Thomas D. Zindrick President, Chief Executive Officer and ChairmanThomas Zindrick holds a scientific background in molecular biology and spent over 30 years in legal, regulatory, and business development roles, including serving as Vice President of Law and Associate General Counsel at Amgen during a period of significant product expansion. He is currently President and CEO of Genelux Corporation, a late-stage biopharmaceutical company developing oncolytic immunotherapies for aggressive solid tumors.

Jason LittenChief Medical OfficerExecutive Officer at Artivabio

Matthew PulisicChief Financial Officer

Joseph CappelloVice President of Pharmaceutical Development

Eric GroenGeneral Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Paul ScigallaNamed on SEC filing

Gabe WoodwardNamed on SEC filing

Mary MirabelliNamed on SEC filing

John ThomasNamed on SEC filing

Doug SamuelsonNamed on SEC filing

James TyreeNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$23.8M disclosed across 2 of 10 rounds · 1900–2025

▶$5.5MraisedJun 2023 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mary MirabelliDirector
Thomas ZindrickExecutive Officer, Director
Doug SamuelsonExecutive Officer
Gabe WoodwardDirector
Paul ScigallaExecutive Officer
James TyreeDirector
John ThomasDirector

Offering amount: $18M
Amount sold: $5.5M
Finders' fees: $200K
First sale: Jun 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$18.3MraisedJun 2023 · 69 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Paul ScigallaExecutive Officer
Gabe WoodwardDirector
Thomas ZindrickExecutive Officer, Director
Mary MirabelliDirector
John ThomasDirector
Doug SamuelsonExecutive Officer
James TyreeDirector

Offering amount: $33.3M
Amount sold: $18.3M
First sale: May 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$141.7Mvaluation at IPOJan 2023 · $6.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Genelux do?: Genelux Corporation develops next-generation immunotherapies for patients with aggressive and difficult-to-treat solid tumors, running clinical trials and offering physician-requested expanded access to its investigational drugs under limited conditions. The company operates in the biotech and oncology therapeutics space.
How much funding has Genelux raised?: Genelux has disclosed $23.8M raised across 2 of its 10 known rounds.
Where is Genelux headquartered?: Genelux is headquartered in Westlake Village, US.